Clinical Trial Goal
To find out:
- The highest dose of MRX-2843 that’s safe to give
- If MRX-2843 is safe and works well to treat ALL, AML or MPAL that has relapsed or is refractory in teens and adults
You may be able to join this trial if you:
- Are 12 years old or older
- Have one of the following diseases that has relapsed or is refractory:
- ALL
- AML
- MPAL
- Do not have acute promyelocytic leukemia
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
MRX-2843 is a small molecule inhibitor that blocks MerTK and FLT3 in certain cells.
You’ll get:
You’ll get:
- MRX-2843 – A pill that you take by mouth 1 time each day. The dose you'll get depends on when you start the trial and how safe it has been
You may continue treatment for as long as the clinical trial doctors think it’s best for your health. You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for about 8 months.
The Food and Drug Administration (FDA) has not yet approved MRX-2843.
Locations
Emory University, Children's Healthcare of AtlantaRECRUITING
Atlanta, Georgia
Melinda Pauly, MD
Emory University - WINSHIP Cancer CenterRECRUITING
Atlanta, Georgia
William Blum, MD
Memorial Sloan Kettering Cancer CenterRECRUITING
New York, New York
Contacts:
- Dr. Neerav Shukla
- Neerav Shukla
Sponsors
lead: Meryx, Inc.
